Chronic ( − )-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats

British Journal of Nutrition - Tập 106 Số 9 - Trang 1337-1348 - 2011
Manuel Gómez‐Guzmán1, Rosario Jiménez1, Manuel Sánchez1, Miguel Romero1, Francisco O’Valle2, R López-Sepúlveda1, Ana María Quintela1, Pilar Galindo1, María José Zarzuelo1, Elvira Bailón1, Eva Delpón3, Francisco Pérez‐Vizcaíno4,3, Juan Duarte1
1Department of Pharmacology, School of Pharmacy, University of Granada, 18071Granada, Spain
2Department of Pathology, School of Medicine, Granada, Spain
3Department of Pharmacology, School of Medicine, University Complutense of Madrid, Madrid, Spain
4Ciber Enfermedades Respiratorias (Ciberes) and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain

Tóm tắt

The present study analysed the effects of the flavanol ( − )-epicatechin in rats after chronic inhibition of NO synthesis with NG-nitro-l-arginine methyl ester (l-NAME), at doses equivalent to those achieved in the studies involving human subjects. Wistar rats were randomly divided into four groups: (1) control-vehicle, (2) l-NAME, (3) l-NAME-epicatechin 2 (l-NAME-Epi 2) and (4) l-NAME-epicatechin 10 (l-NAME-Epi 10). Rats were daily given by oral administration for 4 weeks: vehicle, ( − )-epicatechin 2 or 10 mg/kg. Animals in the l-NAME groups daily received l-NAME 75 mg/100 ml in drinking-water. The evolution in systolic blood pressure and heart rate, and morphological and plasma variables, proteinuria, vascular superoxide, reactivity and protein expression at the end of the experiment were analysed. Chronic ( − )-epicatechin treatment did not modify the development of hypertension and only weakly affected the endothelial dysfunction induced by l-NAME but prevented the cardiac hypertrophy, the renal parenchyma and vascular lesions and proteinuria, and blunted the prostanoid-mediated enhanced endothelium-dependent vasoconstrictor responses and the cyclo-oxygenase-2 and endothelial NO synthase (eNOS) up-regulation. Furthermore, ( − )-epicatechin also increased Akt and eNOS phosphorylation and prevented the l-NAME-induced increase in systemic (plasma malonyldialdehyde and urinary 8-iso-PGF) and vascular (dihydroethidium staining, NADPH oxidase activity and p22phox up-regulation) oxidative stress, proinflammatory status (intercellular adhesion molecule-1, IL-1β and TNFα up-regulation) and extracellular-signal-regulated kinase 1/2 phosphorylation. The present study shows for the first time that chronic oral administration of ( − )-epicatechin does not improve hypertension but reduced pro-atherogenic pathways such as oxidative stress and proinflammatory status of the vascular wall induced by blockade of NO production.

Từ khóa


Tài liệu tham khảo

10.1038/sj.bjp.0704064

Piskula, 1998, Accumulation of ( − )-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues, J Nutr, 128, 1172, 10.1093/jn/128.7.1172

10.1016/S0024-3205(98)00273-2

10.1016/S0008-6363(98)00305-8

10.1016/j.freeradbiomed.2009.10.043

Keen, 2005, Cocoa antioxidants and cardiovascular health, Am J Clin Nutr, 81, 298S, 10.1093/ajcn/81.1.298S

10.1113/expphysiol.1997.sp004025

Sanchez, 2007, Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta, J Nutr, 137, 910, 10.1093/jn/137.4.910

10.1001/jama.290.8.1029

10.1016/j.phrs.2011.03.009

10.1161/HYPERTENSIONAHA.109.147892

10.1016/j.amjcard.2004.02.035

Buijsse, 2006, Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study, Arch Intern Med, 166, 411

10.1002/ptr.3119

10.1161/01.HYP.15.6.699

10.1161/01.HYP.32.6.958

10.1161/01.ATV.18.9.1408

10.1161/01.CIR.101.4.423

Grassi, 2005, Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons, Am J Clin Nutr, 81, 611, 10.1093/ajcn/81.3.611

10.1016/j.abb.2007.10.012

10.1038/oby.2008.60

10.1097/00004872-200312000-00016

10.1016/S0014-2999(97)01311-3

10.1186/1743-7075-3-2

10.1038/ajh.2007.14

10.1161/01.CIR.104.2.151

10.1016/0891-5849(95)02047-0

10.1097/00041552-200401000-00013

10.1161/01.HYP.36.1.103

10.1097/01.hjh.0000198029.22472.d9

10.1016/0306-3623(93)90159-U

10.1042/CS20060185

10.1073/pnas.0510168103

10.1097/00004872-200209000-00031

10.1038/oby.2007.176

Holt, 2002, Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa, Am J Clin Nutr, 76, 798, 10.1093/ajcn/76.4.798

10.1161/01.CIR.95.6.1532

10.1161/01.HYP.0000032031.30374.32

10.1016/0076-6879(90)86134-H

10.1016/j.atherosclerosis.2009.01.036